EMA Clarifies Questions Over Biosimilar Interchangeability
Q&A Document Follows EMA-HMA Statement On Scientific Rationale Last Year
Responding to questions seeking clarifications over a statement on the scientific rationale supporting the interchangeability of biosimilars in the EU, the EMA has issued a supplementary Q&A document to address issues around multiple switches, complexity of molecular structure and national switching policies.
You may also be interested in...
A science-based approach to biosimilars, exemplified by the latest statement from European regulators, makes further progress on biosimilars just a matter of time, according to Gillian Woollett, vice president and head of regulatory strategy and policy at Samsung Bioepis.
In terms of broadening both access to treatment and stakeholder understanding, there remains plenty of room for growth for biosimilars in Europe, Medicines for Europe director general Adrian van den Hoven tells Generics Bulletin in an exclusive interview.
With Europe’s biosimilars industry bolstered by a recent statement from the EMA and HMA, as well as the prospect of a more streamlined regulatory pathway in future, Medicines for Europe’s biosimilars chair Isabell Remus and director of biosimilars policy and science Julie Maréchal-Jamil spoke to Generics Bulletin to discuss the path forward.